Company Profile
Silence Therapeutics Stock Price, News & Analysis
- Ticker:
- SLN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
11.72 USD (+4.27%)
Close
Last updated: August 6, 2026
301M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SLN closed up 4.27% at $11.72. No new same-company headline was identified in the current news window.
Company overview
Business overview
Silence Therapeutics is an RNA interference company focused on targeted gene silencing. Its story is built around translating RNAi into precision medicines for cardiovascular and hematologic disease.
Geographic Base and Sector Classification
Silence Therapeutics is headquartered in the United Kingdom and listed on NASDAQ. It sits in RNA therapeutics and platform biotechnology.
Business Model Characteristics
The company depends on translational validation, clinical progress, and the ability to turn RNAi science into durable therapeutic value. Investors watch data, partnerships, and pipeline execution.
Position Within the Biotechnology Landscape
Silence occupies a premium RNAi niche within biotech. The stock is sensitive to whether the platform can keep validating beyond the first wave of programs.
Future catalysts
Silence Therapeutics’ catalysts are RNAi-platform programs and any clinical update that shows the delivery / target-silencing story still has real momentum. The company remains very platform-dependent.
Recent news
- 01
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
Source: Silence Therapeutics
- 02
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
Source: Silence Therapeutics
- 03
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
Source: Silence Therapeutics
- 04
Silence Therapeutics Begins Exclusive Nasdaq Trading
Source: Silence Therapeutics
- 05
Silence Therapeutics to Present at Jefferies London Healthcare Conference
Source: Silence Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Silence Therapeutics (SLN)?
Silence Therapeutics (SLN) most recently closed at 11.72 USD, a +4.27% move versus the previous session.
What is the market cap of Silence Therapeutics (SLN)?
Silence Therapeutics currently has a market capitalization of 301M USD on BioPharmSignal.
What does Silence Therapeutics do?
Silence Therapeutics is an RNA interference company focused on targeted gene silencing. Its story is built around translating RNAi into precision medicines for cardiovascular and hematologic disease.
On which exchange is SLN stock listed?
Silence Therapeutics (SLN) is associated with NASDAQ, United Kingdom, Biopharma.
What is Silence?
Silence Therapeutics’ catalysts are RNAi-platform programs and any clinical update that shows the delivery / target-silencing story still has real momentum.
Which conditions is Silence Therapeutics targeting with Silence?
Silence Therapeutics is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does Silence Therapeutics describe recent progress with Silence?
Silence Therapeutics’ catalysts are RNAi-platform programs and any clinical update that shows the delivery / target-silencing story still has real momentum.
What is Therapeutics?
Silence Therapeutics is an RNA interference company focused on targeted gene silencing.